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Background: To report a case of peripheral polypoidal choroidal vasculopathy (PCV) which 
was treated successfully.
Methods: Interventional case report. Best-corrected visual acuity measurements (BCVA), 
slit-lamp examination, fundus biomicroscopy, fluorescein angiography (FFA), and indocyanine 
green angiography (ICGA) were performed at baseline examination and during the follow-up 
period. The patient underwent ICGA-guided argon laser to treat the active polyps.
Results: An 82-year-old Caucasian man presented complaining of sudden deterioration of 
peripheral vision in his left eye (LE). His previous ocular history was associated with advanced 
age-related macular degeneration (AMD) involving both eyes (BE). Fundus examination 
revealed macular scars in BE and a large hemorrhagic pigment epithelial detachment (PED) 
temporal to the macula in the LE. ICGA revealed active polyps at the margins of the PED. The 
patient underwent ICGA-guided argon laser to treat the active polyps. Six months post-laser, 
the patient regained his peripheral vision with resolution of the hemorrhagic PED and remains 
stable until now, one year after treatment.
Conclusions: Appropriate treatment and regular follow-up is important in patients with PCV 
and peripheral lesions even if central vision is lost.
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Introduction
Idiopathic polypoidal choroidal vasculopathy (PCV) is an exudative disorder of the 
macula. Although its pathogenesis remains unclear, it is generally thought to be an inner 
choroidal vascular abnormality1 which usually emanates from the posterior pole1 or 
less commonly from the peripheral retina.2 We report a case of PCV in the peripheral 
fundus in a patient with bilateral end-stage age-related macular degeneration (AMD) 
treated successfully.
Case presentation
An 82-year-old Caucasian man presented in our department complaining of sudden 
deterioration of peripheral vision in his left eye (LE). His previous ocular history 
was associated with advanced AMD involving both eyes. Best-corrected visual 
acuity (BCVA) was counting fingers in both eyes. The anterior segments and 
intraocular pressures were within normal limits in both eyes. Fundus examination 
revealed scar formation involving the center of the fovea bilaterally. In addition, a 
large hemorrhagic pigment epithelial detachment (PED) was detected temporal to 
the macula in the LEClinical Interventions in Aging 2009:4 316
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Indocyanine green angiography (ICGA) disclosed the 
presence of actively leaking polypoidal vessels at the margins 
of the PED. The diagnosis of peripheral idiopathic PCV in 
a patient with advance AMD was made. After informed consent 
was obtained, ICGA-guided argon laser photocoagulation 
was applied. Six months post-laser, the hemorrhagic PED was 
resolved. One year later, the patient remains stable and his 
peripheral vision has significantly improved.
Discussion
In 1990, idiopathic PCV was first described by Yannuzzi 
and colleagues1 as a vascular disorder originating from the 
choroidal circulation. This disorder has been recognized 
increasingly in recent years as a distinct clinical entity 
separate from AMD. The pathogenesis of PCV remains 
unclear. Recent genetic research has shown that PCV 
and AMD share common genetic factors3 which may 
suggest that although PCV and wet AMD have differ-
ent clinical characteristics, they may share same similar 
pathophysiologic aspects. In support of the latter, Lafaut 
and colleagues4 reported the possible coexistence of AMD 
and PCV in the same patient histopathologically.
Patients with end-stage AMD, characterized from the 
development of fibrotic tissue in the fovea, experience a 
significant loss of central vision. Peripheral retina is rarely 
affected allowing the patient to maintain some quality in their 
peripheral or side vision. Modifying the patient’s environment 
and using available low vision devices and aids, AMD patients 
can continue to maintain their lifestyle and independence.
Choroidal vascular lesions of PCV are more preferable 
found in the posterior pole of the retina,4 although further 
evidence suggests that the lesion could also be found in the 
peripheral retina up to 63%.3,5
We report a case of peripheral PCV in a male patient 
with advanced bilateral AMD affecting severely both foveal 
areas. The initial complain of the patient was deterioration of 
peripheral vision in addition to the already affected central 
vision. Such a clinical situation may impair significantly 
the quality of life of the patient and needs to be promptly 
identified, diagnosed and treated in order to preserve, in the 
best possible way, the peripheral vision of the patient.
Currently there are many therapeutics options for PCV. 
Photodynamic therapy alone or combined with anti-vascular 
endothelial growth factor treatment showed promising 
results.6 However, use of a conventional argon laser achieved 
up to 78% clinical or angiographic resolution of maculopathy 
for extrafoveal polyps.7 When PCV lesions accompany PED, 
the lesions are usually located at the margins of PED.8 In 
our case, ICGA-guided argon laser photocoagulation was 
selected, since central vision was impaired due to foveal scars 
and the polyp lesions were extrafoveal and at the margins 
of the PED.
In our case, treatment with ICGA-guided argon 
laser photocoagulation was beneficial and resolved the 
hemorrhagic PED, preserving the peripheral vision of the 
patient. Appropriate treatment and regular follow-up is impor-
tant in patients with PCV even if central vision is lost.
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Figure 1 A) Color fundus picture of the right eye of our patient showing a macular 
scar. B) Color-mosaic fundus picture of the left eye (LE) before treatment showing 
a macular scar and a large hemorrhagic pigment epithelial detachment (PED) temporal 
to the fovea resembling a choroidal melanoma. C) Late phase of fluorescein angiography 
of the LE showing hyperfluorescence due to staining of fibrotic tissue at the fovea and 
hypofluorescence due to masking of the hemorrhagic PED temporal to the fovea. D) 
Mid phase of Indocyanine green angiography showing hypofluorescence due to the 
PED with two hot spots at the margins (white arrows).
Abbreviation: PED, pigment epithelial detachment.
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Figure 2 A) Color-mosaic fundus picture of the left eye (LE) six months 
post-ICGA-guided argon laser showing a macular scar and almost complete resolution 
of the hemorrhagic pigment epithelial detachment (PED) temporal to the fovea. The 
appearance remained stable for another six months. B) Late phase of FFA of the LE 
resolution of the PED temporal to the fovea with hyperfluorescence due to staining 
of the fibrotic tissue. C) Late phase of ICGA at the same time showing the area 
corresponding to the PED with no active hot spots.
Abbreviations: FFA, fluorescein angiography; ICG, indocyanine green angiography; 
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